Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenosylhomocysteinase pseudogene 7 (AHCYP7) is a genomic DNA sequence in humans that resembles the functional AHCY gene but contains mutations or sequence changes that disable its ability to produce a functional protein[1][4]. Pseudogenes like AHCYP7 are typically considered non-coding and lack direct biological activity. Some pseudogenes have been implicated in gene regulation and serve as markers in studies of evolutionary genetics and genomic organization, but no therapeutic, diagnostic, or functional role has been established for AHCYP7. Unlike its parent gene (AHCY), it does not encode adenosylhomocysteinase enzyme activity, which catalyzes the hydrolysis of S-adenosylhomocysteine to homocysteine and adenosine—an essential step in methylation cycles[5]. The pseudogene variant, by definition, cannot fulfill these biochemical functions. AHCYP7 is not a valid therapeutic target. It is a nonfunctional pseudogene without characterized biological functions, disease associations, or drug interactions. The entry's main value is for genomic annotation rather than drug discovery, biomarker research, or mechanistic studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenosylhomocysteinase pseudogene 7 (AHCYP7).